Tags : Russian Federation


Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply

Shots: Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy Prestige BioPharma will be responsible for commercial supply the product out of its manufacturing facilities in Osong, Korea Prestige’s (HD204) is currently being evaluated in […]Read More